Furthermore, comparing SGLT2 inhibitors with sulfonylureas, a class notorious for causing hypoglycemia, which is itself a risk factor for cognitive decline, may artificially inflate the apparent benefit of the SGLT2 inhibitor. This evidence concerns the gene SLC5A2 and Mental deterioration.